Email Page Print Page

SEC Filings and Financial Information

NASDAQBDSI
FormDescriptionDateFormat
DEFA14AAdditional proxy soliciting materials - definitiveJun 29, 2011View HTMLDownload DOCDownload PDFDownload XLS
DEF 14AOfficial notification to shareholders of matters to be brought to a vote ("Proxy")Jun 13, 2011View HTMLDownload DOCDownload PDFDownload XLS
PRE 14AA preliminary proxy statement providing notification matters to be brought to a voteJun 1, 2011View HTMLDownload DOCDownload PDFDownload XLS
Top News
Nov 16, 2017

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine, today announced that Dr. Mark A. Sirgo, Vice...

Nov 9, 2017

BioDelivery Sciences International, Inc. (BDSI) today reported financial results for the three and nine months ended September 30, 2017, and provided an update on recent business highlights and...

Oct 30, 2017

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it will report its third quarter 2017 financial results and host a conference call and webcast at 4:30 PM Eastern Time on...

investor inquiries

 

Al Medwar
Senior Vice President, Corporate and Business Development
BioDelivery Sciences International, Inc.
919-582-9050
amedwar@bdsi.com